Keywords: myriad, starts, phase, ii, trial, mpc-7869, usa-based
Myriad starts Phase II trial of MPC-7869
Article | 07 July 2003
USA-based Myriad Genetics has initiated a Phase II trial of MPC-7869 (R-flurbiprofen) in patients with mild-to-moderate Alzheimer's disease. The multicenter, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
